Fabbiani Massimiliano, Terrosi Chiara, Martorelli Barbara, Valentini Melissa, Bernini Laura, Cellesi Carla, Cusi Maria Grazia
Department of Molecular Biology, Infectious Diseases Section, University of Siena, Policlinico "S. Maria delle Scotte", Siena, Italy.
J Med Virol. 2009 Apr;81(4):750-6. doi: 10.1002/jmv.21457.
Impact of recently discovered viruses on epidemiology of acute respiratory tract infections (ARTI) is still unclear. We studied the impact of recently discovered human metapneumovirus (hMPV), human bocavirus (HBoV), and new coronaviruses (HCoV-NL63 and HKU1) on the global epidemiology of ARTI. From October 2006 to April 2007, 237 pediatric patients affected by ARTI were enrolled in our study. Specimens were tested for respiratory viruses by polymerase chain reaction. One hundred twenty-four out of 237 samples (52.3%) were positive for one or more viruses. Picornaviruses were the most prevalent viruses (n = 61, 43.6%), followed by respiratory syncytial virus (n = 34, 24.3%) and Adenovirus (n = 25, 17.9%); hMPV (n = 9, 6.4%) was the fourth most common virus detected. HBoV and HCoV showed a low prevalence (respectively 2.9% and 2.1%). RSV was the prevalent agent of LRTI (38%). Viruses were identified in more than 50% of the studied ARTI, providing useful information on clinical features and epidemiology of specific agents affecting children in cold months. Although routine surveillance of respiratory viruses does not seem cost-effective, continuous monitoring of ARTI etiology could be a useful tool for planning resources for the development of new vaccines and antiviral agents.
最近发现的病毒对急性呼吸道感染(ARTI)流行病学的影响仍不明确。我们研究了最近发现的人偏肺病毒(hMPV)、人博卡病毒(HBoV)和新型冠状病毒(HCoV-NL63和HKU1)对ARTI全球流行病学的影响。2006年10月至2007年4月,237名患有ARTI的儿科患者参与了我们的研究。通过聚合酶链反应对标本进行呼吸道病毒检测。237份样本中有124份(52.3%)一种或多种病毒检测呈阳性。微小核糖核酸病毒是最常见的病毒(n = 61,43.6%),其次是呼吸道合胞病毒(n = 34,24.3%)和腺病毒(n = 25,17.9%);hMPV(n = 9,6.4%)是检测到的第四常见病毒。HBoV和HCoV的流行率较低(分别为2.9%和2.1%)。呼吸道合胞病毒是下呼吸道感染(LRTI)的主要病原体(38%)。在所研究的ARTI病例中,超过50%检测出病毒,这为寒冷月份影响儿童的特定病原体的临床特征和流行病学提供了有用信息。尽管对呼吸道病毒进行常规监测似乎不具有成本效益,但持续监测ARTI的病因可能是规划新疫苗和抗病毒药物研发资源的有用工具。